MediPharm Labs Corp. LABS
TSX · Canada · Process Industries
CAD 0.07000.00 (0.00%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
MediPharm Labs Corp (MEDIF) reports record adjusted EBITDA and positive net income, driven by a 26% surge in international medical cannabis revenue.
Q2 2026 Adjusted EBITDA1 of $0.9M, the Company’s strongest quarterly performance since 20192Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025OPEX decreased 44% in Q2 2026 versus Q2 2025Net Revenue of $10.0M, an increase of 11% versus Q1 2026 with German revenue increasing 45% sequentially and 33% year over yearCash of $9.9M consistent with Q1 2026, and the Company remains virtually debt free, with outright ownership of two production facilities appraised at over $15MPo
TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three and six months ended June 30th, 2026, before markets open on Thursday, August 13th, 2026. MediPharm Labs executive management team will also host a conference call and webcast on August 13t
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.